U.S. markets closed
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • Dow 30

    33,926.01
    -127.89 (-0.38%)
     
  • Nasdaq

    12,006.96
    -193.84 (-1.59%)
     
  • Russell 2000

    1,985.53
    -15.69 (-0.78%)
     
  • Crude Oil

    73.23
    -0.16 (-0.22%)
     
  • Gold

    1,877.70
    +1.10 (+0.06%)
     
  • Silver

    22.40
    -0.01 (-0.04%)
     
  • EUR/USD

    1.0796
    -0.0115 (-1.06%)
     
  • 10-Yr Bond

    3.5320
    +0.1360 (+4.00%)
     
  • GBP/USD

    1.2035
    -0.0194 (-1.58%)
     
  • USD/JPY

    132.0070
    +3.4030 (+2.65%)
     
  • BTC-USD

    22,906.91
    -517.17 (-2.21%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.36 (+0.39%)
     

Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com